| Protocol | Description | Details |
| SWOG-S0221 | Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
| Randomized: Yes
Principal Investigator(s):
Christy Russell
Staff Members:
Chit Galam
Joanne Sakamoto
Greg Jackson
Yvonne Flores
Jessica Levano
|
| SWOG-S0230 | Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
| Randomized: Yes
Principal Investigator(s):
Agustin Garcia
Staff Members:
Chit Galam
Joanne Sakamoto
Yvonne Flores
Jessica Levano
|
| SWOG-S0307 | Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Other
| Randomized: Yes
Principal Investigator(s):
Agustin Garcia
Staff Members:
Joanne Sakamoto
Yvonne Flores
Anayansi Miloud
Jessica Levano
|
| SWOG-S0337 | A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Local
| Randomized: Yes
Principal Investigator(s):
Eila Skinner
Staff Members:
Charlean Ketchens
Lagrimas Ilagan
Roberto Tejada
|
| SWOG-S0421 | Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
| Randomized: Yes
Principal Investigator(s):
David Quinn
Staff Members:
Charlean Ketchens
Lagrimas Ilagan
Roberto Tejada
Carrie Korn
|
| SWOG-S0500 | A Randomized Phase III Trial to Test the Strategy of Changing Therapy versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
| Randomized: Yes
Principal Investigator(s):
Darcy Spicer
Staff Members:
Chit Galam
Joanne Sakamoto
Yvonne Flores
Jessica Levano
|
| SWOG-S0518 | Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Hormone
Immunotherapy
Anti-Angiogenesis
| Randomized: Yes
Principal Investigator(s):
Syma Iqbal
Staff Members:
Noureddine Miloud
|
| SWOG-S0533 | A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
Radiation: External
Anti-Angiogenesis
| Randomized: No
Principal Investigator(s):
Barbara Gitlitz
Staff Members:
Charlean Ketchens
Lagrimas Ilagan
Gina Tse
Eduardo Mejia
|
| SWOG-S0711 | Phase I Pharmacokinetic Study of Dasatinib (BMS-354825) (NSC-732517; IND-73969) in Patients with Advanced Malignancies and Varying Levels of Liver Dysfunction.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
| Randomized: No
Principal Investigator(s):
Anthony El-Khoueiry
Staff Members:
Claire Hughlett
Mary Ordaz
Anayansi Miloud
Xiomara Menendez
|
| SWOG-S0713 | A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab, and Radiation in Pre-Operative Therapy of Rectal Cancer.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
Radiation: External
Surgery
Immunomodulator
| Randomized: No
Principal Investigator(s):
Heinz Josef Lenz
Staff Members:
Noureddine Miloud
Carol Jones
|
| SWOG-S0715 | Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine (ALC) for the Prevention of Taxane-Induced Neuropathy, Phase III.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Other
| Randomized: Yes
Principal Investigator(s):
Agustin Garcia
Staff Members:
Chit Galam
Joanne Sakamoto
Yvonne Flores
Jessica Levano
|
| SWOG-S0720 | Phase II ERCC1 and RRM1-Based Adjuvant Therapy Trial in Patients with Stage I Non-Small Cell Lung Cancer (NSCLC).
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
| Randomized: No
Principal Investigator(s):
Barbara Gitlitz
Staff Members:
Charlean Ketchens
Lagrimas Ilagan
Gina Tse
Eduardo Mejia
|
| SWOG-S0727 | A Phase I and Randomized Phase II Trial of Gemcitabine + Erlotinib (NSC-718781) + IMC-A12 (NSC-742460) vs. Gemcitabine + Erlotinib as First-Line Treatment in Patients with Metastatic Pancreatic Cancer.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
Immunotherapy
| Randomized: Yes
Principal Investigator(s):
Anthony El-Khoueiry
Staff Members:
Noureddine Miloud
Carol Jones
|
| SWOG-S0809 | A Phase II Trial of Adjuvant Capecitabine/Gemcitabine Chemotherapy Followed by Concurrent Capecitabine and Radiotherapy in Extrahepatic Cholangiocarcinoma (EHCC).
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Chemotherapy: Systemic
Radiation: External
| Randomized: No
Principal Investigator(s):
Anthony El-Khoueiry
Staff Members:
Noureddine Miloud
Carol Jones
|
| SWOG-S9808 | Long Term Follow-up Protocol: Administrative Tool.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
| Randomized: No
Principal Investigator(s):
David Quinn
Staff Members:
|
| SWOG-S9910 | Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
Other
| Randomized: No
Principal Investigator(s):
Alan Yang
Staff Members:
Kristy Watkins
|
| SWOG-S9925 | Lung Cancer Specimen Repository Protocol, Ancillary.
Click on protocol number to see eligibility requirements
Protocol Treatment Modalities:
| Randomized: No
Principal Investigator(s):
Barbara Gitlitz
Staff Members:
Charlean Ketchens
Lagrimas Ilagan
Vatche Stepanian
Gina Tse
|
